Zobrazeno 1 - 10
of 11 273
pro vyhledávání: '"radionuclide therapy"'
Autor:
Jordan Cheng, Joke Zink, Edward O’Neill, Bart Cornelissen, Julie Nonnekens, Lefteris Livieratos, Samantha Y. A. Terry
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Background Peptide receptor radionuclide therapy (PRRT) uses [177Lu]Lu-[DOTA0-Tyr3]octreotate ([177Lu]Lu-DOTA-TATE) to treat patients with neuroendocrine tumours (NETs) overexpressing the somatostatin receptor 2A (SSTR2A). It has shown signi
Externí odkaz:
https://doaj.org/article/c2dfe895678c431e9e12583837aa8980
Autor:
Hao Zhang, Takahiro Tsuchikawa, Satoshi Takeuchi, Kenji Hirata, Kimitaka Tanaka, Aya Matsui, Yoshitsugu Nakanishi, Toshimichi Asano, Takehiro Noji, Toru Nakamura, Shintaro Takeuchi, Masataka Wada, Satoshi Hirano
Publikováno v:
Endocrine Journal, Vol 71, Iss 9, Pp 873-880 (2024)
As novel biomarkers for gastroenteropancreatic neuroendocrine tumors (GEPNET) are in demand, we aimed to validate the clinical value of the NETest in Japanese patients. Between 2021 and 2023, blood and clinical data were collected from patients with
Externí odkaz:
https://doaj.org/article/39465c1aa9dc4078afadaefabe35b0aa
Publikováno v:
Endocrine Oncology, Vol 4, Iss 1, Pp 1-8 (2024)
There is interest in optimizing peptide receptor radionuclide therapy (PRRT) for the management of metastatic neuroendocrine neoplasms (NEN). The addition of stereotactic body radiation therapy (SBRT) may provide synergistic benefits by targeting spe
Externí odkaz:
https://doaj.org/article/bad2904e60284b3882ef5ce3fab878eb
Autor:
Mei-Fang Cheng, Chih-Chieh Yen, Jeng-Shiun Du, Yu-Li Chiu, Ming-Huang Chen, Hui-Jen Tsai, I-Chen Wu, Hueng-Yuan Shen, Ruoh-Fang Yen, Li-Tzong Chen, On Behalf of Taiwan Neuroendocrine Tumor Society and Taiwan Society of Nuclear Medicine
Publikováno v:
Journal of Cancer Research and Practice, Vol 11, Iss 2, Pp 57-61 (2024)
Objective: The current study aimed to investigate the basic principles and clinical applications, including the selection of proper candidates, follow-up strategies, and radiation protection issues relating to peptide receptor radionuclide therapy (P
Externí odkaz:
https://doaj.org/article/d84971adb08f42978f5f06cfebdd3568
Autor:
Dheeratama Siripongsatian, Quido G de Lussanet de la Sablonière, Frederik Anton Verburg, Tessa Brabander
Publikováno v:
Endocrine Oncology, Vol 4, Iss 1, Pp 1-9 (2024)
The field of nuclear theranostic clinical trials is continuously expanding as an increasing number of novel agents and treatment combinations are explored for treating advanced and metastatic cancers. Moving from ‘bench-to-bedside’ is oftentimes
Externí odkaz:
https://doaj.org/article/29686f7548ec4061a35ac44b26056c6c
Publikováno v:
Journal of Isotopes, Vol 38, Iss 2, Pp 185-194 (2024)
Medical isotopes are the substantial basis of the diagnostic and therapeutic nuclear medicine. There are irreplaceable advantages for utilizing the nuclear medical technology to diagnose and treat the malignant tumors, cardiovascular and cerebrovascu
Externí odkaz:
https://doaj.org/article/15b9cf8e3f8e4983a80a18411a047ac5
Autor:
Christof Rottenburger, Michael Hentschel, Markus Fürstner, Lisa McDougall, Danijela Kottoros, Felix Kaul, Rosalba Mansi, Melpomeni Fani, A. Hans Vija, Roger Schibli, Susanne Geistlich, Martin Behe, Emanuel R. Christ, Damian Wild
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Background A new generation of radiolabeled minigastrin analogs delivers low radiation doses to kidneys and are considered relatively stable due to less enzymatic degradation. Nevertheless, relatively low tumor radiation doses in patients in
Externí odkaz:
https://doaj.org/article/b2acaa6880e14783bd5cb5fd43fcbc99
Autor:
Dagmar Grob, Bastiaan M. Privé, Constantijn H. J. Muselaers, Niven Mehra, James Nagarajah, Mark W. Konijnenberg, Steffie M. B. Peters
Publikováno v:
EJNMMI Physics, Vol 11, Iss 1, Pp 1-12 (2024)
Abstract Background Bone marrow toxicity in advanced prostate cancer patients who receive [177Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention o
Externí odkaz:
https://doaj.org/article/6dbce80e4d6b49a5afe0d91156498091
Autor:
Alexis M. Sanwick, Ivis F. Chaple
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Head and neck squamous cell carcinoma (HNSCC) is a type of head and neck cancer that is aggressive, difficult to treat, and often associated with poor prognosis. HNSCC is the sixth most common cancer worldwide, highlighting the need to develop novel
Externí odkaz:
https://doaj.org/article/831aa26a32e74924a2e32087efb2db5d
Autor:
Egesta Lopci, Federica Matteucci
Publikováno v:
Frontiers in Nuclear Medicine, Vol 4 (2024)
Externí odkaz:
https://doaj.org/article/572c908605134f29bd56f03d204def24